RT Journal Article
SR Electronic
T1 Identification of Serum Proteins Related to Adverse Effects Induced by Docetaxel Infusion from Protein Expression Profiles of Serum Using SELDI ProteinChip System
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1197
OP 1203
VO 25
IS 2B
A1 HEIKE, YUJI
A1 HOSOKAWA, MAMI
A1 OSUMI, SHOZO
A1 FUJII, DAISUKE
A1 AOGI, KENJIRO
A1 TAKIGAWA, NAGIO
A1 IDA, MIKIKO
A1 TAJIRI, HISAO
A1 EGUCHI, KENJI
A1 SHIWA, MIEKO
A1 WAKATABE, RUMI
A1 ARIKUNI, HISASHI
A1 TAKAUE, YOICHI
A1 TAKASHIMA, SHIGEMITSU
YR 2005
UL http://ar.iiarjournals.org/content/25/2B/1197.abstract
AB Background: For the development of quick and easy methods for screening and identifying treatment-responsive proteins, we determined the protein expression profile of the serum after docetaxel infusion using a surface-enhanced laser desorption/ionization time-of-flight mass spectroscopy (SELDI TOF-MS) system. Materials and Methods: Blood from breast cancer patients was collected before and 4, 8, 24 and 48 hours after docetaxel infusion. The protein expression profile was determined by a SELDI TOF-MS system. The relative expression levels of target proteins were compared during the time-course after docetaxel injection. Results: We identified two representative proteins with molecular weights of 7790 Da and 9285 Da. The 7790 Da protein was high molecular weight kininogen, and the 9285 Da protein was apolipoprotein A-II. These two proteins had similar expression patterns in 5 patients, except one patient who experienced severe, acute, adverse effects. Conclusion: These results suggest that protein expression profiles determined by SELDI TOF-MS represent useful data for the identification of treatment-responsive proteins. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved